Literature DB >> 15202514

Trends in pharmacogenomics of drugs acting on hypertension.

Roberto Trotta1, Maria Benedetta Donati, Licia Iacoviello.   

Abstract

With the recent rapid increase in scientific understanding of the human genome it is becoming possible to identify the extent to which genetic variations influence drug response. The emergence of pharmacogenetics heralds a new era in which drug therapies will be selected on the basis of differences in individuals' genotypes, enhancing drug safety and efficacy. The major focus of this review is pharmacogenetics of antihypertensive drugs. Genetics can influence the pharmacokinetics and pharmacodynamics of such drugs at different levels. The presently available applications of genetic concepts to some drugs commonly used in the treatment of hypertension (ACE-inhibitors, diuretics, beta-blockers...) will be summarized. Also sensitivity to salt intake will be considered as an example of pharmacogenetics. The identification of genetic markers of drug response will help to achieve a better control of blood pressure in the population, by allowing a better tailor of antihypertensive therapy to individual patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15202514     DOI: 10.1016/j.phrs.2003.07.018

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  3 in total

1.  Changes in the usage of antihypertensive drugs: implications and prospects.

Authors:  Mike Schachter
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

2.  Association of the antihypertensive response of iptakalim with KCNJ11 (Kir6.2 gene) polymorphisms in Chinese Han hypertensive patients.

Authors:  Rui-feng Duan; Wen-yu Cui; Hai Wang
Journal:  Acta Pharmacol Sin       Date:  2011-07-18       Impact factor: 6.150

3.  Mutational analysis of the Kir6.1 gene in Chinese hypertensive patients treated with the novel ATP-sensitive potassium channel opener iptakalim.

Authors:  Ruifeng Duan; Wenyu Cui; Hai Wang
Journal:  Exp Ther Med       Date:  2011-04-28       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.